Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · S-3

Quoin Pharmaceuticals Ltd.

SEC Filing

Filed Sep 18, 2026Accepted Sep 18, 2026, 5:00 PM EDTCIK 1671502Accession 0001104659-26-108970
Share

Company context

Quoin Pharmaceuticals Ltd. Is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Current securities

Historical securities (2)

Recent company filings

  1. PRE 14A filingSep 22, 2026
  2. Regulation FD Disclosure · Other EventsSep 22, 2026
  3. D filingSep 10, 2026
  4. Regulation FD Disclosure · Other EventsSep 10, 2026
  5. 4 filingAug 28, 2026

As-filed source

Primary evidence